Global expansion Medical Union Pharmaceuticals (MUP) has established a transnational footprint across over 30 countries and aims to become a top five international manufacturer in Egypt, Africa, East Europe, and the MENA region, presenting a sales opportunity to partners and distributors in emerging markets and regional buyers seeking diversified supplier networks.

Strategic production MUP operates modern manufacturing facilities with state-of-the-art lines and recently began Cephalosporin, Penicillin, and human insulin production (InsulinEgypt), signaling capabilities to supply high-demand biologics and essential medicines to hospital networks, clinics, and public procurement programs.

Insulin footprint As the first national Egyptian company to acquire a multinational insulin factory and launch InsulinEgypt, MUP presents a strong opportunity to engage with endocrinology and diabetes care channels, including hospital formularies, wholesalers, and specialty distributors seeking reliable insulin sourcing.

Logistics access Located near major logistics hubs including Ain Sokhna port, Suez, Port Said, and Cairo Airport, MUP can leverage efficient distribution to regional markets, enabling partnerships with distributors, contract manufacturers, and export-focused suppliers seeking near-shore manufacturing and rapid replenishment.

Market growth With revenue in the low to mid single digits and a clear growth trajectory toward internationalization, MUP offers opportunities for tiered partnerships, co-marketing, contract manufacturing, and expansion into public sector tenders, research collaborations, and private healthcare networks.